Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 9/20 | 0.49 |
| ▸ | EDNRB | P24530 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29095265 | 0.76 | HPGD (0.49) | MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL28493442 | 0.72 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7677604 | 0.66 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL19392334 | 0.64 | KMT2A (0.75) | MEN1KMT2ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10022415 | 0.63 | ALOX5 (0.44) | CHEK2 | |
| SCHEMBL19127455 | 0.62 | TSHR (0.69) | MEN1KMT2ACHEK2SMN1; SMN2MAPT | |
| Acetic Acid SCHEMBL28970013 | 0.62 | TSHR (0.69) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| Propane SCHEMBL7392630 | 0.62 | TSHR (0.69) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2846313 | 0.62 | ADRB3 (0.47) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL10073975 | 0.62 | MAPT (0.57) | MEN1KMT2ASMN1; SMN2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207989-A1 | DITERPENE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR, CANCER AND INFLAMMATORY DISEASES | SAVIPU PHARMACEUTICALS (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207989-A1 | DITERPENE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR, CANCER AND INFLAMMATORY DISEASES | NFKBIA, EDNRA, EDNRB | EDNRA 2/4885EDNRB 3/4885MEN1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.